Oculis Holding AG Ordinary shares

Yahoo Finance • 10 hours ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCS

NEW YORK, June 16, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Oculis Holding AG (“Oculis” or the “Company”) (NASDAQ: OCS). Such investors are advised to contact Danielle Peyton at newaction@p... Full story

Yahoo Finance • 6 days ago

Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026

ZUG, Switzerland, June 11, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs... Full story

Yahoo Finance • 8 days ago

Oculis Announces First Patient Randomized in PREDICT-1 Registrational Trial of Licaminlimab, Advancing Precision Medicine in Dry Eye Disease

PREDICT-1 is the first genotype-based registrational trial in dry eye disease (DED), with the potential of delivering a first-in-class precision medicine treatment in DED This FDA-aligned trial targets the specific TNFR1 genotype to maxim... Full story

Yahoo Finance • 9 days ago

Nan Fung Group Sells $4.3 Million in Oculis Shares As Lead Drug Stumbles

What happened According to a recent SEC filing, Nan Fung Group Holdings Ltd reduced its position in Oculis(NASDAQ:OCS) by 163,957 shares during the first quarter of 2026. The estimated value of the trade was $4.3 million, based on the qua... Full story

Yahoo Finance • 14 days ago

Trevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters.

Pivotal bioVenture Partners Investment Advisor increased its position in Trevi Therapeutics(NASDAQ:TRVI) during the first quarter, acquiring 296,944 shares in an estimated $3.32 million trade based on average quarterly pricing, according t... Full story

Yahoo Finance • 18 days ago

Oculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular Edema

The primary endpoint of mean change in best corrected visual acuity (BCVA) from baseline to week 52 in both Phase 3 trials was not met The secondary endpoint of retinal thickness showed a substantial and persistent reduction with OCS-01 vs... Full story

Yahoo Finance • last month

Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting

ZUG, Switzerland, May 05, 2026 (GLOBE NEWSWIRE) -- Key findings from the DME AWARE initiative highlight the importance of non-invasive treatment options for early intervention in diabetic macular edema (DME) managementOculis is on track... Full story

Yahoo Finance • 2 months ago

Oculis to Present at Upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Latest findings from the DME AWARE Delphi Study on unmet needs in diabetic macular edema (DME) management highlighting the need for non-invasive therapeutic options to be presented by Baruch Kuppermann, M.D., Ph.D.New post-hoc analysis of... Full story

Yahoo Finance • 3 months ago

Oculis to Present at Upcoming North American Neuro-Ophthalmology Society Annual Meeting

ZUG, Switzerland, March 16, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology... Full story

Yahoo Finance • 4 months ago

Oculis Appoints Katie Kazem as Chief Legal Officer

Ms. Kazem brings extensive and global expertise in corporate governance and securities law, drawing on a distinguished track record as external legal counsel to leading life sciences companiesChief Legal Officer (CLO) appointment enhances... Full story

Yahoo Finance • 7 months ago

Pre-Market Earnings Report for November 18, 2025 : HD, PDD, MDT, BIDU, ESLT, AS, BZ, JHX, BRBR, ENR, WB, OCSL

The following companies are expected to report earnings prior to market open on 11/18/2025. Visit our Earnings Calendar for a full list of expected earnings releases. Home Depot, Inc. (HD)is reporting for the quarter ending October 31... Full story

Yahoo Finance • 7 months ago

Oculis Holding GAAP EPS of CHF -0.32

* Oculis Holding press release [https://seekingalpha.com/pr/20301359-oculis-reports-q3-2025-financial-results-and-provides-company-update] (OCS [https://seekingalpha.com/symbol/OCS]): Q3 GAAP EPS of CHF -0.32. * Operating income of CHF... Full story

Yahoo Finance • 7 months ago

Oculis Reports Q3 2025 Financial Results and Provides Company Update

ZUG, Switzerland, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Oculis accelerates its portfolio development with Privosegtor moving into the PIONEER pivotal program in Acute Optic Neuritis (AON) andNon-arteritic Anterior Ischemic Optic Neuropathy... Full story

Yahoo Finance • 7 months ago

Oculis birtir uppgjör fyrir þriðja ársfjórðung 2025 og kynnir áfanga í rekstri félagsins

ZUG, Sviss, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Oculis hraðar þróunaráætlun sinni í kjölfar árangursríks fundar með Matvæla- og lyfjastofnun Bandaríkjanna (FDA), með PIONEER-rannsóknaráætluninni á Privosegtor sem meðferð við bráðri sjónta... Full story

Yahoo Finance • 7 months ago

Oculis to Participate in Upcoming November Investor Conferences

ZUG, Switzerland, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophtha... Full story

Yahoo Finance • 8 months ago

Oculis Announces Oversubscribed $110 Million Financing to Accelerate Privosegtor Development

ZUG, Switzerland, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs... Full story

Yahoo Finance • 8 months ago

Oculis greinir frá umframeftirspurn í 110 milljóna USD fjármögnun sem er ætlað til að hraða klínískri þróun Privosegtor

ZUG, Sviss, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) („Oculis“ eða „félagið“), alþjóðlegt líftæknilyfjafyrirtæki með áherslu á á nýsköpun til að meðhöndla augnsjúkdóma og augntaugasjúkdóma og mæta veru... Full story

Yahoo Finance • 8 months ago

Oculis to Spotlight Transformative Late-Stage Pipeline at Eyecelerator and AAO 2025

ZUG, Switzerland, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on developing innovations for ophthalmic and neuro-ophthalmic diseases with significan... Full story

Yahoo Finance • 8 months ago

Oculis Accelerates Privosegtor into Registrational Trials in Acute Optic Neuritis, Pioneering the Path for a Potential First-in-class Neuroprotective Therapy

Successful meeting with FDA enables advancement into pivotal development with Privosegtor in Acute Optic Neuritis (AON) and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) Oculis will launch the PIONEER Program, which includes mu... Full story

Yahoo Finance • 8 months ago

Oculis hrindir af stað skráningarrannsóknum á Privosegtor við bráðri sjóntaugabólgu, sem gæti orðið fyrsta taugaverndandi meðferð sinnar tegundar

ZUG, Sviss, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Árangursríkur fundur með Matvæla- og lyfjastofnun Bandaríkjanna (FDA) skapar möguleika á að hefja skráningarrannsóknir á Privosegtor sem meðferð við bráðri sjóntaugabólgu (e. Acute Optic Neur... Full story